UNASSIGNED: Three experiments were done to better assess the gastrointestinal (GI) site(s) of action of @entity15212 on food intake in @entity35 . First, near-spontaneous nocturnal chow @entity5562 ( @entity5562 ), intermeal intervals (IMI) length and satiety ratios (SR  =  @entity5562 /IMI) were measured after infusion of saline, 0.025 or 0.5  nmol/kg @entity15212 into the celiac artery (CA, supplying the stomach and upper duodenum), cranial mesenteric artery (CMA, supplying small and all of the large intestine except the rectum), femoral artery (FA, control) or portal vein (PV, control). Second, infusion of 0.5  nmol/kg @entity15212 was tested after pretreatment with the @entity17121 ( @entity17121 ) antagonist exendin-4(3-39) via the same routes. Third, the regional distribution of @entity17121 in the @entity35 GI tract was determined using rtPCR. CA, CMA and FA @entity15212 reduced first @entity5562 relative to saline, with the CMA route more effective than the others. Only CMA @entity15212 prolonged the IMI. None of the infusions affected second @entity5562 or later eating. CA and CMA @entity15212 increased the SR, with the CMA route more effective than the CA route. CMA exendin-4 (3-39) infusion reduced the effect of CMA @entity15212 . Finally @entity17121 expression was found throughout the GI tract. The results suggest that exogenous @entity15212 acts in multiple GI sites to reduce feeding under our conditions and that @entity17121 in the area supplied by the CMA, i.e., the small and part of the large intestine, plays the leading role.

Exogenous glucagon-like peptide-1 acts in sites supplied by the cranial mesenteric artery to reduce @entity5562 and prolong the intermeal interval in XXXX .

@entity35 :: ('10116', 'Species') :: ['rat', 'rats'] @entity15212 :: ('24952(Tax:10116)', 'Gene') :: ['GLP-1'] @entity5562 :: ('MESH:D015875', 'Disease') :: ['meal size', 'MS'] @entity17121 :: ('25051(Tax:10116)', 'Gene') :: ['GLP-1 receptor', 'GLP-1R']
@entity35 :: (10116,Species) :: ['rats']
